We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0Q1N market cap is 167.13B. The company's latest EPS is USD 0.3753 and P/E is 78.58.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 59.84B | 41.91B | 81.29B | 100.33B | 58.5B |
| Operating Income | 18.48B | 6.77B | 19.82B | 34.96B | -2.3B |
| Net Income | 16.27B | 9.62B | 21.98B | 31.37B | 2.12B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 167.49B | 154.23B | 181.48B | 197.21B | 226.5B |
| Total Liabilities | 104.04B | 90.76B | 104.01B | 101.29B | 137.21B |
| Total Equity | 63.45B | 63.47B | 77.46B | 95.92B | 89.29B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 12.59B | 14.4B | 32.58B | 29.27B | 8.7B |
| Investing | -3.95B | -4.27B | -22.55B | -15.78B | -32.28B |
| Financing | -8.49B | -9.65B | -9.82B | -14.83B | 26.07B |
| Market Cap | 167.13B |
| Price to Earnings Ratio | 78.58 |
| Price to Sales Ratio | 2.85 |
| Price to Cash Ratio | 58.36 |
| Price to Book Ratio | 1.86 |
| Dividend Yield | - |
| Shares Outstanding | 5.65B |
| Average Volume (1 week) | 53.29k |
| Average Volume (1 Month) | 81.26k |
| 52 Week Change | -23.71% |
| 52 Week High | 41.20 |
| 52 Week Low | 25.30 |
| Spread (Intraday) | 2.7 (8.82%) |
| Company Name | Pfizer Inc |
| Address |
235 east 42nd street new york, new york 10017 |
| Website | https://www.pfizer.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
